Oncology ASCO 2024 – Thanos Zomas Great advances in cancer care have led to a new phase of research in certain cancers – in areas where a high rate of cure has been established, the focus is shifting to quality of life, sid
Views & Analysis Cutting the combination therapy access issue down to size While the access to combination treatments problem is nothing new, its sheer magnitude means it has, to date, gone unsolved.
R&D Ben Sidders on integrating causality in AI for R&D success Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face